PHS
ALLO icon

PFM Health Sciences’s Allogene Therapeutics ALLO Stock Holding History

PFM Health Sciences’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-775,819
Closed -$19.9M – 73
2021
Q3 		$19.9M Buy
775,819
+169,019
+28% +$4.01M 0.59% 53
2021
Q2 		$15.8M Buy
606,800
+16,422
+3% +$468K 0.5% 55
2021
Q1 		$20.8M Buy
+590,378
New +$19.9M 0.64% 52
2020
Q4 		– Sell
-224,266
Closed -$8.46M – 86
2020
Q3 		$8.46M Buy
+224,266
New +$8.46M 0.39% 65
2019
Q1 		– Sell
-617,193
Closed -$16.6M – 94
2018
Q4 		$16.6M Buy
+617,193
New +$16.4M 0.44% 62

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFM Health Sciences's ALLO Position: Q4 2021 in Review

PFM Health Sciences sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 775,819 shares — an estimated $19.9M sold.

PFM Health Sciences first reported a position in ALLO in Q4 2018 and held it in 5 quarters. The position peaked at $20.8M in Q1 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • PFM Health Sciences reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • PFM Health Sciences sold 775,819 Allogene Therapeutics shares in Q4 2021, an estimated $19.9M.
  • PFM Health Sciences first reported a position in Allogene Therapeutics in Q4 2018 and held it in 5 quarters.
  • PFM Health Sciences's Allogene Therapeutics position peaked at $20.8M in Q1 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.